41st week of 2019 patent applcation highlights part 8 |
Patent application number | Title | Published |
20190307756 | Methods and Compositions for Treating Thyroid-Related Medical Conditions with Reduced Folates - The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein. | 2019-10-10 |
20190307757 | Edible Energy Composition - The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested. | 2019-10-10 |
20190307758 | TRPA1 ANTAGONISTS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS - The present invention relates to a TRPA1 receptor antagonist for use in preventing and/or treating the inflammatory component of atopic dermatitis. | 2019-10-10 |
20190307759 | PRESERVATIVE FREE BRIMONIDINE AND TIMOLOL SOLUTIONS - The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma. | 2019-10-10 |
20190307760 | ACC INHIBITORS FOR USE IN TREATING MYCOBACTERIAL DISEASES - The invention relates to inhibitors of the host acetyl-CoA-carboxylase (ACC) for use in treating mycobacterial diseases and to pharmaceutical compositions containing such inhibitors for said use. The invention further relates to a kit of parts comprising a pharmaceutical composition containing such inhibitors and at least one additional pharmaceutically active compound. | 2019-10-10 |
20190307761 | AGENT FOR SUPPRESSING POST-SURGICAL CANCER RECURRENCE AND/OR METASTASIS - The inventors found that postsurgical recurrence and/or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery. | 2019-10-10 |
20190307762 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMA AND STRESSOR-RELATED DISORDERS - The present invention relates to methods for the treatment or prevention of symptoms associated with trauma and stressor-related disorders, in which exposure to a traumatic or stressful event is listed explicitly as a diagnostic criterion. These include reactive attachment disorder, disinhibited social engagement disorder, post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorders. The present invention also relates to pharmaceutical compositions comprising opipramol alone, or in combination with another agent for the treatment or prevention of symptoms associated with trauma and stressor-related disorders. The present invention also relates to transdermal formulations of pharmaceutical compositions comprising opipramol alone, or in combination with another agent, for the treatment or prevention of symptoms associated with trauma and stressor-related disorders. | 2019-10-10 |
20190307763 | SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF - Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic herteocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity. | 2019-10-10 |
20190307764 | METHODS OF TREATMENT OF PARTIAL ONSET SEIZURES USING ESLICARBAZEPINE ACETATE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 2019-10-10 |
20190307765 | METHODS OF TREATMENT OF PARTIAL ONSET SEIZURES USING ESLICARBAZEPINE ACETATE - The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate. | 2019-10-10 |
20190307766 | CYCLIC AMINES - The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor. | 2019-10-10 |
20190307767 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. | 2019-10-10 |
20190307768 | OPHTHALMIC COMPOSITION FOR LOWERING INTRAOCULAR PRESSURE - The present invention relates to an ophthalmic composition for lowering an intraocular pressure, the composition comprising latanoprost, polyoxyl 40 hydrogenated castor oil, and sorbitol. | 2019-10-10 |
20190307769 | Hypotensive lipid-containing biodegradable intraocular implants and related methods - Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma. | 2019-10-10 |
20190307770 | METHODS FOR TREATING OR PREVENTING CANCER IN A KRAS-VARIANT PATIENT AND FOR DIAGNOSING RISK OF DEVELOPING MULTIPLE PRIMARY BREAST TUMORS - The invention relates to methods for preventing cancer in a KRAS-variant subject which include administering to the KRAS-variant subject an amount of estrogen effective to reduce the risk of developing cancer. In another aspect, the invention further relates to methods for treating cancer in a KRAS-variant subject, which include gradually decreasing estrogen exposure in the KRAS-variant subject to reduce the risk of aggressive tumor growth. In another aspect, the invention relates to a method of predicting an increased risk of developing a second, independent breast cancer in a subject. The method can include detecting a single nucleotide polymorphism (SNP) at position 4 of the let-7 complementary site 6 of KRAS in a patient sample wherein the presence of said SNP indicates an increased risk of developing a second, independent cancer in said subject. | 2019-10-10 |
20190307771 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES - The invention provides methods and pharmaceutical compositions for treating cancer or a metabolic disease in a subject. In some aspects, the invention comprises administering to the subject a therapeutically effective amount of a retinoid and a histone deacetylase (HDAC) inhibitor. In some embodiments, the HDAC inhibitor is a short-chain fatty acid and/or suberanilohydroxamic acid (SAHA). In other aspects, the invention comprises administering to the subject a therapeutically effective amount of a microRNA. Pharmaceutical compositions and kits for treating a subject with cancer or a metabolic disease are also provided herein. | 2019-10-10 |
20190307772 | PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE - The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g., in a male patient having a condition associated with symptoms of deficiency or absence of endogenous testosterone. | 2019-10-10 |
20190307773 | METHODS FOR TREATING TESTOSTERONE DEFICIENCY IN MEN AND METHODS FOR PRECISE DOSING OF UGT2B17 SUBSTRATE DRUGS - Treatment of testosterone deficiency in men by a precision medicine approach using a biomarker of activity of UGT2B17 that is involved in testosterone urinary elimination. By inhibiting UGT2B17, alone or in combination with administration of testosterone, testosterone deficiency in men can be treatable. Further, a method of dose selection for precise dosing of UGT2B17 substrate drugs is provided. Additionally, methods for safe dosing of pharmaceutical agents that undergo UGT2B17-mediated acyl glucuronidation are provided. | 2019-10-10 |
20190307774 | COMPOSITION AND METHOD TO AID IN HORMONE REPLACEMENT THERAPY - A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of jojoba oil, evening primrose oil, and borage seed oil. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy. | 2019-10-10 |
20190307775 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 2019-10-10 |
20190307776 | AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, aza-substituted triterpenoid compounds that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: | 2019-10-10 |
20190307777 | COMPLEXES OF CELECOXIB AND ITS SALTS AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Disclosed herein are stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Celecoxib, its salts, or derivatives thereof, which is useful in the treatment of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain especially in cancer related acute pain, primary dysmenorrhea. More specifically, the complexes possess instantaneous redispersibility, increased apparent solubility and permeability that provide faster onset of action for acute pain relief and lower GI related side effects. Further disclosed are methods of formulating and manufacturing the complexes described herein, pharmaceutical compositions, and uses and methods of treatment. | 2019-10-10 |
20190307778 | TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES - Methods of treatment and dosage regimes using a composition comprising a tetracycline antibiotic in treating or alleviating a disorder including EGFRI associated rash, EGFRI associated rash related symptoms, a tetracycline antibiotic responsive EGFRI associated rash related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, P. EGFRI associated rash bacteria associated disorders and other superficial infections, including skin infections are provided. | 2019-10-10 |
20190307779 | NOVEL FORMULATIONS - Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof. | 2019-10-10 |
20190307780 | Anti-Inflammatory Compounds and Uses Thereof - Compounds of the general formula | 2019-10-10 |
20190307781 | Treating Tumors with TTFields and an Aurora Kinase Inhibitor - The viability of cancer cells can be reduced by administering an Aurora kinase inhibitor (e.g., MLN8237 or another Aurora A kinase inhibitor, AZD1152 or another Aurora B kinase inhibitor) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 300 kHz (e.g., 200 kHz) to the cancer cells. Furthermore, cancer (e.g., glioblastoma) in a subject may be treated by administering an Aurora kinase inhibitor to the subject, and applying an alternating electric field with frequency between 100 and 300 kHz (e.g., 200 kHz) to a target region of the subject (e.g., the brain). | 2019-10-10 |
20190307782 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS COMPRISING DNA METHYLTRANSFERASE INHIBITORS - The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor. | 2019-10-10 |
20190307783 | USE OF ANTIVIRALS TO INHIBIT PROTOZOAN VIRUSES - The present disclosure relates to compositions comprising anti-viral therapeutics and methods of use thereof in killing parasites. Also described are methods of treating a parasitic infection; methods of screening a library for compounds effective in treating parasitic infections; and methods of diagnosing a parasitic infection. | 2019-10-10 |
20190307784 | APTAMERS REDUCE SICKLE HEMOGLOBIN POLYMERIZATION - The presently disclosed subject matter provides methods for reducing sickling of an erythrocyte comprising sickle hemoglobin (HbS) by introducing polynucleotide aptamers into the erythrocyte. The polynucleotide aptamers specifically bind to HbS to inhibit polymerization of the HbS without affecting the oxygen affinity of the HbS. | 2019-10-10 |
20190307785 | COMPOSITIONS COMPRISING CIRCULAR POLYRIBONUCLEOTIDES AND USES THEREOF - This invention relates generally to pharmaceutical compositions and preparations of circular polyribonucleotides and uses thereof. | 2019-10-10 |
20190307786 | MICRORNA IN T CELL ACTIVATION - Disclosed herein are methods for treating an immune system condition and/or altering T cell activation in a subject. Also disclosed herein are methods for diagnosing an immune system condition in a subject. In some examples, the methods can include measuring expression of at least one T cell activation-related miRNA in a sample obtained from a subject. The methods further include administering to the subject a therapeutically effective amount of an miRNA or mimic thereof, and/or an inhibitor of miRNA or mimic thereof and/or administering to the subject T cells contacted with an effective amount of miRNA or mimic thereof, and/or an inhibitor of miRNA or mimic thereof. | 2019-10-10 |
20190307787 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Provided herein are compositions and methods for treating cancer. In particular, provided herein are compositions, methods, and uses of inhibitors of ARlnc1 for treating cancer. | 2019-10-10 |
20190307788 | METHOD FOR PRODUCING PROTEASE DEGRADATION COMPOSITION - Disclosed is a method for producing a protease degradation composition by degrading a composition containing a hyaluronic acid and a protein with a protease, in the presence of an ascorbic acid, an ascorbate or a salt thereof. The composition produced according to the method has a high fibroblast proliferation promoting effect and a high collagen production promoting effect. | 2019-10-10 |
20190307789 | HyperOsmolar Composition of Hyaluronic Acid - The invention relates to a novel hyperosmolar composition of hyaluronic acid for the use thereof in the treatment of conical oedema. | 2019-10-10 |
20190307790 | METHOD AND APPARATUS FOR ESTABLISHING A KEY AGREEMENT PROTOCOL - A system and method for generating a secret key to facilitate secure communications between users. A first and second and a function between the two monoids are selected, the function being a monoid homomorphism. A group and a group action of the group on the first monoid is selected. Each user is assigned a submonoid of the first monoid so that these submonoids satisfy a special symmetry property determined by the function, a structure of the first and second monoids, and the action of the group. A multiplication of an element in the second monoid and an element in the first monoid is obtained by combining the group action and the monoid homomorphism. First and second users choose private keys which are sequences of elements in their respective submonoids. A first result is obtained by multiplying an identity element by the first element of the sequence in a respective submonoid. Starting with the first result, each element of the user's private key may be iteratively multiplied by the previous result to produce a public key. Public keys are exchanged between first and second users. Each user's private key may be iteratively multiplied by the other user's public key to produce a secret key. Secure communication may then occur between the first and second user using the secret key. | 2019-10-10 |
20190307791 | USE OF FERRIC CITRATE IN THE TREATMENT OF AND THE REDUCTION OF MORTALITY AND MORBIDITY RELATED TO ADVERSE CARDIAC EVENTS IN CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed. | 2019-10-10 |
20190307792 | MINERAL SALT-SULFONIC ACID COMPOSITIONS AND METHODS OF USE - The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions. | 2019-10-10 |
20190307793 | METHOD OF ENABLING MUSCLE RELAXATION - A method of application to human skin of a water solution or an emulsion of water and oil of metallic salts at concentrations from 1 to not more than 10 times the normal concentration found in the interstitial cellular space in humans, including the addition of ADP, ATP, and various manual, impulse, light or electrical therapy. | 2019-10-10 |
20190307794 | METHOD FOR INDUCING TRANSDIFFERENTIATION OF IMMUNE CELLS BASED ON EXOSOMES - The present invention relates to a method of inducing trans-differentiating a first type of immune cell into a second type of immune cell comprising: isolating exosomes from the second type of immune cell that has undergone differentiation, and treating the first type of immune cell or a cell population including the first type of immune cell with the isolated exosomes in vitro. | 2019-10-10 |
20190307795 | REGULATORY T CELLS TARGETED WITH CHIMERIC ANTIGEN RECEPTORS - Regulatory T cells (Treg) are engineered to express a chimeric antigen receptor (CAR), that specifically binds folate receptor beta; and are administered to an individual for treatment of inflammation at sites characterized by the presence of activated myeloid cells. Also provided are methods for utilized engineered T regulatory cells to enhance hematopoietic cell transplantation. | 2019-10-10 |
20190307796 | USE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA (PGC1ALPHA) AGONISTS TO IMPROVE EX VIVO EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) - The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods. | 2019-10-10 |
20190307797 | CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND BCMA - The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and/or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases. | 2019-10-10 |
20190307798 | CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE - Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised. | 2019-10-10 |
20190307799 | ENGINEERED LYMPHOCYTES - Provided here are compositions comprising engineered lymphocytes that secrete bispecific engager molecules, thereby activating T cells in the local environment to kill target cells. In particular embodiments, engineered lymphocytes selectively target CLL-1 positive leukemic cells, both directly and through activation of a subject's own T cells, while sparing CLL-1 negative cells, such as myeloid progenitor cells. In particular embodiments, engineered lymphocytes selectively target CD123 and CLL-1 positive leukemic cells, both directly and through activation of native T cells. | 2019-10-10 |
20190307800 | METHODS FOR OFF-THE-SHELF-TUMOR IMMUNOTHERAPY USING ALLOGENEIC T-CELL PRECURSORS - The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy. | 2019-10-10 |
20190307801 | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-10-10 |
20190307802 | PROBIOTIC COMPOSITIONS INCLUDING IMMUNE MODULATORS - A digestive product includes a probiotic component and an immune modulator, such as transfer factor and/or a nanofraction immune modulator. The digestive product may also contain a prebiotic component, such as one or more of galactooligosaccharides, xylooligosaccharides, and fructooligosaccharides. The probiotic component may be encapsulated, such as probiotic micro beadlets. | 2019-10-10 |
20190307803 | COMPOSITIONS FOR ESTABLISHING MIXED CHIMERISM AND METHODS OF MANUFACTURE THEREOF - The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34 | 2019-10-10 |
20190307804 | CELLULAR COMPOSITIONS DERIVED FROM PRIOR ORGAN DONORS AND METHODS OF MANUFACTURE AND USE THEREOF - The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34 | 2019-10-10 |
20190307805 | METHOD OF TRANSPORTING MESENCHYMAL STEM CELLS BY MEANS OF A TRANSPORTING SOLUTION AND A METHOD OF ADMINISTERING STEM CELLS TO WOUNDS - The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population. | 2019-10-10 |
20190307806 | PLURIPOTENT STEM CELL THAT INDUCES REPAIR AND REGENERATION AFTER MYOCARDIAL INFARCTION - An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders. | 2019-10-10 |
20190307807 | CELL PREPARATION - To provide a spheroid-containing cell preparation exhibiting a high therapeutic effect for a cartilage tissue-related disorder as a treatment target. | 2019-10-10 |
20190307808 | TREATMENT OF CANAVAN DISEASE - Disclosed herein are methods of treating Canavan disease in a subject through restoring ASPA enzymatic activities in the subject by expressing exogenous wild type ASPA gene in the brain of the subject. Also disclosed are a process of producing neural precursor cells, including NPCs, glial progenitor cells and oligodendroglial progenitor cells, which express an exogenous wild type ASPA gene and the neural precursor cells produced by this process. | 2019-10-10 |
20190307809 | METHODS AND COMPOSITIONS FOR IN VIVO INDUCTION OF PANCREATIC BETA CELL FORMATION - Embodiments of the invention stimulate three levels of beta cell physiology: (i) glucose metabolism, (ii) membrane receptor function, and (iii) transcriptional factors that result in the in vivo formation of beta cells in the pancreas for the purpose of treating diabetes. | 2019-10-10 |
20190307810 | METHODS FOR PRODUCING HORMONE SECRETING CELLS IN A SUBJECT - A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation. | 2019-10-10 |
20190307811 | METHOD FOR TREATING AIRWAYS DISEASE - The present disclosure teaches a method for treating airways disease including ameliorating symptoms of airway inflammation, airway remodeling and airway hyper-responsiveness. The method comprises the administration of an anti-fibrotic agent together with amnion epithelial cells or their functional equivalents or exosomes. | 2019-10-10 |
20190307812 | MICRONIZED WHARTON'S JELLY - The present invention provides compositions and formulations of micronized Wharton's jelly having a controlled viscosity such that when delivered to the injured region of a subject, it remains substantially localized with little or no migration out of the injured region for the repair and/or regeneration thereof. Micronized Wharton's Jelly can be suspended in a pharmaceutically acceptable aqueous carrier, such as saline, sterile water, or any suitable buffer, to form a suspension or a gelatinous gel composition, or it can be in the form of a paste, suitable for delivery into the space adjacent the articular surface cartilage injured region of a subject. The micronized Wharton's jelly when employed at sufficient concentrations can be hydrated into a gel or paste and administered topically, or it can be injected into the body through the use of a needle and syringe. Accordingly, micronized Wharton's Jelly, compositions, or formulations thereof, can be delivered in a manner that is more convenient than Wharton's jelly that has not been micronized in accordance with the present invention. | 2019-10-10 |
20190307813 | Method and System for Treating Cancer and Other Age-Related Diseases by Extending the Healthspan of a Human - Various embodiments of the present invention are directed to the field of Oncology, and in particular, embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. Certain embodiments are directed to the field of human longevity and aging in a manner such that cancer is not contracted due to ameliorating, treating, or reducing aging by increasing the healthspan and lifespan of humans. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g. tomatidine, rapamycin, p53 protein, statins, etc., is employed to treat and prevent cancer and other age-related diseases. | 2019-10-10 |
20190307814 | PRE-FERMENTED SYMBIOTIC MATRIX BASED ON A CEREAL SUSPENSION WITH ENCAPSULATED PROBIOTICS, MANUFACTURE PROCESS AND CORRESPONDING UTILIZATION - A pre-fermented symbiotic matrix based on a cereal suspension containing encapsulated probiotics and prebiotics, the manufacturing process and the corresponding use are disclosed. The invention complements the actual functional food market solving problems inherent to reduced shelf-life of foods due to loss of probiotic viability to values below the minimum limits needed to promote biological activity. The invention also improves the enzymatic process in the preparation of the cereal base and the fermentative process conditions at different levels, namely the ability to control the concentration of sugars in the cereal suspension without adding sugars, increase protein and fiber content, reduce fermentation time to reduce energy consumption during the process and reduce the risk of contamination as well as promote long term microbial stability maintenance. The invention is designed for cases where intolerance and/or allergy to dairy products occur, as wells for the pharmaceutical, cosmetic and food industries, including pet food. | 2019-10-10 |
20190307815 | BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS - This invention relates to new uses of | 2019-10-10 |
20190307816 | Probiotic Formulation and Method for Weight Loss Treatment - A composition of probiotics is provided which promotes weight loss and maintenance thereof. More particularly, a probiotic mixture of | 2019-10-10 |
20190307817 | MEDICINAL VAGINAL LACTOBACILLUS COCKTAIL - Described herein are methods and compositions for the use of treating and/or preventing vaginal bacterial infection and promoting healthy vaginal flora. Aspects of the invention relate to administering to a subject in need thereof a composition comprising a bacterial mixture of | 2019-10-10 |
20190307818 | NOVEL ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE - The invention relates to compositions for inhibiting or agonizing quorum sensing (QS) pathways to repress biofilm formation, biofilm streamer formation, virulence factor production, and/or infections (including bacterial infections and bacterial infections with resistance to antibiotics) by: (a) a monotherapy using novel compounds, such as small molecule inhibitors or agonists, to inhibit or activate QS activation pathways and/or (b) a combination therapy including novel compounds to inhibit or activate QS and/or to sensitize bacteria to phage along with phage therapy. These compositions can be used to treat patients having infections. Additionally, these compositions can be used to treat surfaces/areas known to contain human pathogens notorious for causing hospital-acquired infections (such as intravenous catheters, implants, medical devices) as well as fatal infections that occur outside of health care settings. Preferred microorganisms that can be treated with the compositions of the invention include, but are not limited to bacterial strains resistant to one or more antibiotics. | 2019-10-10 |
20190307819 | STABILISATION OF VIRAL PARTICLES - A method for preserving viral particles comprising: (a) providing an aqueous solution of (i) viral particles, (ii) optionally one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating said viral particles. | 2019-10-10 |
20190307820 | COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUS - The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity). | 2019-10-10 |
20190307821 | METHODS AND COMPOSITIONS FOR CANCER THERAPY - Improved cancer therapies are provided and include methods for inhibiting growth of tumor cells in an individual by administering to the individual a polynucleotide encoding a protein that contains an immunoglobulin Fc and an antagonist peptide of a receptor expressed by tumor cells, and administering a chemotherapeutic agent to the individual, such that the growth of the tumor cells and/or metastasis of cancer cells is synergistically inhibited. Approaches are also provided for improving cancer therapies that include adoptive immunotherapies by using the polynucleotides to enhance tumor infiltration by immune cells. | 2019-10-10 |
20190307822 | ORAL COMPOSITIONS AND METHODS FOR ANIMALS - The present invention is directed to methods and compositions for treating, preventing, or minimizing bad breath in an animal, including administering compositions comprising honey and spirulina. | 2019-10-10 |
20190307823 | YEAST EXTRACT HAVING DIABETES PREVENTION EFFECT - [Problem] To provide an agent suppressing an increase in blood sugar level, said agent being capable of controlling blood sugar level even in a patient having normal blood sugar level or a patient corresponding to pre-diabetes, showing little side effects and being derived from a safe food. Also, the present invention addresses the problem of providing foods and drinks, i.e., foods including health foods, functional foods, health supplements, etc. as well as drinks, each comprising the aforesaid composition. [Solution] An extract of yeast to be used as an active ingredient. As the extract of yeast, it was found that a yeast extract, which can be obtained by a simple procedure comprising treating a yeast with hot water, an acid or an alkali, and/or an enzyme, has an improved effect of suppressing an increase in blood sugar level. | 2019-10-10 |
20190307824 | Enhanced Herb or Food Product and Method - The present invention is a method of preparing and potentiating functional foods and, in particular, herbs, by subjecting the food or herb to specific method steps, either a particular three- or four- step potentiating process or a specific infusion/fermentation potentiating technique, for which in some embodiments the fermentation is optional. | 2019-10-10 |
20190307825 | Pharmaceutical Compositions Containing Cannabis, Uses Thereof and Methods for Improving Sleep Quality - A pharmaceutical composition containing cannabis for improving the quality of sleep in a patient is provided. Also provided are a use of the pharmaceutical composition for improving the quality of sleep in a patient, and methods for improving the quality of sleep. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, and/or an herb. | 2019-10-10 |
20190307826 | Pharmaceutical Compositions Containing Cannabis, Uses Thereof and Methods for Improving Energy Levels and/or Alleviating Fatigue - A pharmaceutical composition containing cannabis for increasing energy levels and/or alleviating fatigue in a patient. Also provided are a use of the pharmaceutical composition for increasing energy levels and/or alleviating fatigue in a patient, and methods for increasing energy levels and/or alleviating fatigue. The pharmaceutical composition preferably includes a combination of therapeutically effective amounts of one or more of the following medicinal ingredients: cannabis, an herb, vitamins, and/or fructose. | 2019-10-10 |
20190307827 | METHOD FOR INHIBITING EXPRESSION OF ICAM-1 GENE - A method for inhibiting the expression of ICAM-1 gene is provided, wherein the method comprises administering to a subject in need an effective amount of an euryale seed extract. The method is especially for treating, preventing or regulating diseases or physiological functions associated with ICAM-1 gene. | 2019-10-10 |
20190307828 | DIETARY VEGAN SUPPLEMENT FOR TREATING JOINT PAIN - The present disclosure relates to a dietary vegan supplement for treating joint pain in human comprising of natural ingredients as its constituents. The composition for the dietary vegan supplement for treating joint pain in human comprises of natural vitamin E (d-alpha-tocopherol), turmeric root extract (standardized to 95% curcuminoids), a plant material (devils claw) providing a rich source of harpagosides, calcium carbonate powder, green tea extract comprising standardized 90% polyphenols, 80% catechins, ginger, olive extract (olive oil powder), glucosamine HCL, flaxseed or flaxseed extracts thereof, and black pepper extract standardized to contain 95% piperine. In addition, the compositions provided herein can contain other ingredients such as vitamin D3 (cholecalciferol). | 2019-10-10 |
20190307830 | COMPOSITIONS TARGETING THE INTERACTION DOMAIN BETWEEN P27KIP1 AND BRK AND METHODS OF USE THEREOF TO INHIBIT P27 Y PHOSPHORYLATION AND CDK4 ACTIVITY - Compositions and methods for the treatment of malignancy are disclosed. | 2019-10-10 |
20190307831 | MATERIALS AND METHODS FOR TREATMENT OF INFLAMMATION - The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation. | 2019-10-10 |
20190307832 | INHIBITORS OF VALOSIN-CONTAINING PROTEIN AND METHODS OF USE - A method of inhibiting aberrant valosin-containing protein (VCP) accumulation in the mitochondria of a nerve cell includes administering to the nerve cell a therapeutic agent that inhibits the binding or complexing of VCP with a polyglutamine protein. | 2019-10-10 |
20190307833 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH NEUROTROPHIC PEPTIDERGIC COMPOUND - The treatment of age-related macular degeneration with the chronic administration of the neurotrophic peptidergic compound P021. Chronic treatment of animal models for age-related macular degeneration prevented the pathological changes associated with age-related macular degeneration, including photoreceptor degeneration, lipofuscin granules, vacuoles and atrophy in retinal pigment epithelium (RPE), Bruch's membrane (BM) thickening, rosette-like structure formation, microgliosis and astrogliosis. | 2019-10-10 |
20190307834 | COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS - Provided are novel peptides, methods of their preparation and their use in controlled release of pharmaceutically active compounds. | 2019-10-10 |
20190307835 | MODULATORS OF COMPLEMENT ACTIVITY - The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics. | 2019-10-10 |
20190307836 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES - The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer. | 2019-10-10 |
20190307837 | CASPOFUNGIN COMPOSITIONS FOR INHALATION - Compositions and corresponding methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein. | 2019-10-10 |
20190307838 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS - The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy | 2019-10-10 |
20190307839 | Enzyme Replacement Therapy for Melanoma - The most frequent cause of melanoma is Ultraviolet Radiation, which produces defects in DNA namely dimerisation of nucleotids in the same chain. There are in nature cases of particular resistance to UV radiation, namely the fungus | 2019-10-10 |
20190307840 | POLYPEPTIDES FOR MANAGING VIRAL INFECTIONS - Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides and compositions disclosed herein to treat or prevent a viral infection. | 2019-10-10 |
20190307841 | USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS - The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease. | 2019-10-10 |
20190307842 | PHARMACEUTICAL COMPOSITIONS AND METHODS TARGETING WNT PATHWAY PROTEINS - Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner. Also provided are methods of using the compositions. | 2019-10-10 |
20190307843 | SINGLE DOSE METHODS FOR PREVENTING AND TREATING FUNGAL INFECTIONS - Provided herein are methods for treating, mitigating, or preventing fungal infections or related conditions thereto in a human subject in need thereof. The methods include the administration of a single dose of a pharmaceutical composition comprising or consisting of CD101 and any pharmaceutically acceptable excipients, wherein the single dose treatment substantially reduces or eliminates the fungal infection. | 2019-10-10 |
20190307844 | METHODS OF TREATING DISEASES RESULTING FROM A MALADAPTED STRESS RESPONSE - The present invention relates to methods for reversing maladaptations involving the corticotropin-releasing factor receptor subtype 2 (CRFR2). It is postulated that in functional somatic syndrome (FSS), a group of diseases with overlapping symptoms, including systemic exertion intolerance disease (SEID, also known as chronic fatigue syndrome or myalgic encephalomyelitis), and several others, this receptor is up-regulated and relocated to the neuronal membranes of key regions of the brain including the raphe nuclei, the limbic system and the cortex. This configuration leads to a dysfunctional stress response. According to one embodiment of the invention, a method for reversing CRFR2 maladaptations includes the sustained stimulation of the receptor over a period of time to bring about a persistent receptor endocytosis, resulting in measurable symptom improvement. | 2019-10-10 |
20190307845 | USE OF SYNTHETIC HISTONE-BINDING REGULATOR PROTEIN PcTF TO ACTIVATE SUPPRESSION OF CANCER CELL GROWTH - Compositions and methods for suppressing cancer cell growth by a synthetic chromatin effector. For example, a synthetic histone-binding regulator protein, polycomb-based transcription factor (PcTF), is utilized to activate suppression of cancer cell growth. Accordingly, an exemplary method disclosed herein may directly target a generally conserved feature, such as elevated trimethyl-lysine 27 on histone H3 (H3K27me3), with PcTF. In addition, a set of 19 PcTF-upregulated genes, or PUGs, that were consistent across three distinct breast cancer cell lines, were identified. These genes are associated with the interferon response pathway. The results demonstrate for the first time a chromatin-mediated interferon-related transcriptional response driven by an engineered fusion protein that physically links repressive histone marks with active transcription. | 2019-10-10 |
20190307846 | METHODS FOR PROMOTING WOUND HEALING AND HAIR GROWTH - The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages. | 2019-10-10 |
20190307847 | METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS - Provided herein are variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics). In some embodiments, these variants and fusions modulate bile acid homeostasis, and are useful in treatment of bile acid related and associated disorders. In some embodiments, these variants and fusions have glucose lowering activity, and are useful in treatment of hyperglycemia and other disorders. | 2019-10-10 |
20190307848 | METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS - The present invention refers to soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications as medication in cognition-related neurological disorders, in particular schizophrenia, Alzheimer's and Parkinson's diseases. | 2019-10-10 |
20190307849 | METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS - Methods of treating subjects having a cancer-related, immune-related, or viral-related disease, disorder or condition via administration of an IL-10 agent, including pegylated IL-10, and an IL-7 agent are provided, as are methods of identifying subjects that may be responsive to treatment with an IL-10 agent. | 2019-10-10 |
20190307850 | COMPOSITION FOR INHIBITING SURVIVAL OR GROWTH OF TUBERCLE BACILLUS BY ADJUSTING POLARIZATION OF MACROPHAGE, AND METHOD USING SAME - The present invention provides a composition for inhibiting the survival or growth of a tubercle bacillus, containing a material which induces the polarization of a macrophage into an M1 macrophage, and a method for inhibiting the survival or growth of the tubercle bacillus by using the composition. | 2019-10-10 |
20190307851 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR RETT SYNDROME (RTT) COMPRISING GHRELIN AS ACTIVE INGREDIENT - A prophylactic and therapeutic agent for Rett Syndrome (RTT) is provided, a pharmaceutical composition comprising ghrelin and a pharmaceutically acceptable carrier and a prophylactic and therapeutic agent for RTT comprising a therapeutically effective amount of ghrelin. The side chain of serine at the 3rd position of ghrelin is modified with octanoic acid. | 2019-10-10 |
20190307852 | TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY - Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide. | 2019-10-10 |
20190307853 | Use of Ultrarapid Acting Insulin - Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. | 2019-10-10 |
20190307854 | ALLELIC VARIANTS OF HUMAN FACTOR VIII - Disclosed are compositions and methods related to Factor VIII. | 2019-10-10 |
20190307855 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 2019-10-10 |
20190307856 | Arginine And Its Use As A T Cell Modulator - The present invention provides novel uses and methods for T cell based immunotherapies. Specifically, the invention relates to novel ligands, targets and nucleic acids and vectors encoding said targets that are useful for modulating T cell responses. | 2019-10-10 |